Brief Description |
Valsartan is a potent, selective and orally active AT1 receptor antagonist (Ki = 2.38 nM), with over 30, 000-fold selectivity over AT2 receptors. It is an investigational antihypertensive drug being studied for use in combination with AHU-377 (molar ratio: 1:1) (Our Prod No. CT-AHU377). The combination drug, known as LCZ696, is in clinical trials for the treatment of heart failure. |
References |
1. L. Criscione, et al, Pharmacological profile of Valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype, Br J Pharmacol, 1993, Oct; 110(2):761-71
2. S. Hanafy, et al, Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers, Br J Pharmacol, 2008 Jan; 153(1):90-9
3. A. A. Voors, et al., The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug. 22(8):1041-7. |